However, in a drug-repurposing effort, ATRA, an FDA-approved drug for the treatment of acute promyelocytic leukemia (APL), has also been shown to be a non-covalent Pin1 inhibitor. This evidence concerns the gene PIN1 and acute promyelocytic leukemia.